Stockscreener 앱 받기
29.66
2.79%
-0.85
시장 영업 전:
28.25
-1.41
-4.75%
Tg Therapeutics Inc 주식(TGTX)의 최신 뉴스
A Look at TG Therapeutics's Upcoming Earnings Report - Benzinga
TG Therapeutics faces earnings test as Briumvi growth accelerates - Investing.com India
TG Therapeutics (TGTX) Set to Announce Q4 Earnings with Positive Revisions - GuruFocus
FOMO Trade: Is TG Therapeutics Inc a top pick in the sectorWeekly Stock Summary & Precise Entry and Exit Recommendations - baoquankhu1.vn
Goldman Sachs raises TG Therapeutics, Inc. (TGTX) target to $39 on 2026 guidance - MSN
Aug Rallies: Is TG Therapeutics Inc undervalued by DCF analysisWeekly Investment Report & Expert Curated Trade Setup Alerts - baoquankhu1.vn
TG Therapeutics, Inc. (TGTX) Stock Analysis: A 50% Upside Potential In Biotech - DirectorsTalk Interviews
TG Therapeutics (TGTX) Earnings Expected to Grow: What to Know Ahead of Q4 Release - Finviz
TG Therapeutics to Host Conference Call Discussing Q4 and Full Year 2025 Financial Results and 2026 Outlook - Quiver Quantitative
TG Therapeutics to Host Conference Call on Fourth Quarter and Full Year 2025 Financial Results and Business Update - marketscreener.com
Hussman Strategic Advisors Sells 126,000 TG Therapeutics Shares - AOL.com
What are TG Therapeutics Inc.’s recent SEC filings showing2025 EndofYear Setup & Safe Capital Preservation Plans - mfd.ru
What is TG Therapeutics Inc.’s valuation compared to sectorDay Trade & Smart Swing Trading Alerts - mfd.ru
Persistent Asset Partners Ltd Sells 71,539 Shares of TG Therapeutics, Inc. $TGTX - MarketBeat
Will TG Therapeutics Inc. benefit from AI trendsForecast Cut & AI Enhanced Trading Signals - mfd.ru
TG Therapeutics, Inc. Announces the Publication of Long Term/Five-Year Data from the Ongoing Open-Label Extension of the Phase 3 Ultimate I and Ii Studies - marketscreener.com
5-year MS study: BRIUMVI patients average one relapse every 50 years - Stock Titan
Liquidity Mapping Around (TGTX) Price Events - Stock Traders Daily
Portfolio Shifts: Should you avoid TG Therapeutics Inc stock right now2025 Investor Takeaways & Free Expert Verified Stock Movement Alerts - baoquankhu1.vn
TG Therapeutics, Inc. (TGTX) Stock Analysis: A 55.89% Potential Upside in the Biotech Space - DirectorsTalk Interviews
What are TG Therapeutics Inc.’s growth leversJuly 2025 Technicals & Weekly Chart Analysis and Trade Guides - mfd.ru
TG Therapeutics, Inc. $TGTX Shares Bought by Public Sector Pension Investment Board - MarketBeat
TG Therapeutics, Inc. (NASDAQ:TGTX) Receives Average Rating of "Moderate Buy" from Brokerages - MarketBeat
TG Therapeutics (NASDAQ:TGTX) Downgraded by Wall Street Zen to "Hold" - MarketBeat
TGTX Stock Price, Forecast & Analysis | TG THERAPEUTICS INC (NASDAQ:TGTX) - ChartMill
Goldman Sachs Raises TG Therapeutics, Inc. (TGTX) Target to $39 on 2026 Guidance - Insider Monkey
Should you avoid TG Therapeutics Inc. stock right now2025 Sector Review & Free Risk Controlled Daily Trade Plans - mfd.ru
Why TG Therapeutics Inc. (NKB2) stock gets analyst attentionTrade Entry Report & Community Supported Trade Ideas - mfd.ru
10 Best Long Term Healthcare Stocks to Buy - Insider Monkey
TG Therapeutics (TGTX) sees price target drop from JPMorgan - MSN
Should New BRIUMVI Data and MS Campaign Shift TG Therapeutics' (TGTX) Narrative on Commercial Execution? - Yahoo Finance
TG Therapeutics lights up Super Bowl with Christina Applegate MS campaign — retail sees 'huge win' - MSN
TG Therapeutics Lights Up Super Bowl With Christina Applegate MS Campaign — Retail Sees 'Huge Win' - Stocktwits
MSFT Vs AMZN Vs GOOGL: Which Cloud Stock Is A Better Bet? - Stocktwits
TG Therapeutics Announces Collaboration with Christina Applegate to Raise Awareness of Multiple Sclerosis - GlobeNewswire
Christina Applegate fronts new MS honesty campaign with TG Therapeutics - Stock Titan
TG Therapeutics Partners with Christina Applegate to Raise MS Awareness - intellectia.ai
TG Therapeutics (TGTX) Sees Price Target Drop from JPMorgan - Finviz
TG Therapeutics presents BRIUMVI data at ACTRIMS forum By Investing.com - Investing.com Nigeria
TG Therapeutics stock pops as Briumvi boom reignites bull case: Goldman Sachs sees room for 32% rally - MSN
TG Therapeutics Presents BRIUMVI Data at ACTRIMS Annual Meeting - Intellectia AI
TG Therapeutics presents BRIUMVI data at ACTRIMS forum - Investing.com
TG Therapeutics rises on new data for autoimmune therapy - TradingView
TG Therapeutics Presents New Data on BRIUMVI® at ACTRIMS 2026 Annual Forum - Quiver Quantitative
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab) in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum - The Manila Times
Real-world and pediatric MS data put BRIUMVI under spotlight at ACTRIMS - Stock Titan
1.52%
1.68%
자본화:
|
볼륨(24시간):